IFRX | InflaRx N.V. | [NASD]
Index- P/E- EPS (ttm)-0.64 Insider Own13.10% Shs Outstand44.77M Perf Week-8.39%
Market Cap221.36M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float37.62M Perf Month-14.78%
Income-28.50M PEG- EPS next Q-0.31 Inst Own9.50% Short Float / Ratio1.88% / 0.28 Perf Quarter114.47%
Sales- P/S- EPS this Y39.20% Inst Trans-20.00% Short Interest0.71M Perf Half Y66.00%
Book/sh1.88 P/B2.21 EPS next Y88.60% ROA-25.60% Target Price9.60 Perf Year209.70%
Cash/sh1.37 P/C3.02 EPS next 5Y- ROE-28.80% 52W Range0.78 - 7.25 Perf YTD33.87%
Dividend- P/FCF- EPS past 5Y8.10% ROI- 52W High-42.76% Beta0.99
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low434.66% ATR0.33
Employees48 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)45.72 Volatility4.15% 7.41%
OptionableYes Debt/Eq0.02 EPS Q/Q21.80% Profit Margin- Rel Volume0.07 Prev Close4.16
ShortableYes LT Debt/Eq0.01 EarningsMar 23 BMO Payout- Avg Volume2.49M Price4.15
Recom1.80 SMA20-8.68% SMA505.25% SMA20048.16% Volume164,663 Change-0.24%
Date Action Analyst Rating Change Price Target Change
Apr-05-23Upgrade Guggenheim Neutral → Buy $8
Feb-28-22Downgrade Guggenheim Buy → Neutral
Oct-28-21Upgrade Raymond James Outperform → Strong Buy $10 → $14
Mar-11-21Upgrade Guggenheim Neutral → Buy $16
Nov-06-20Upgrade SVB Leerink Mkt Perform → Outperform $7 → $10
Oct-08-20Initiated H.C. Wainwright Buy $11
Jun-17-20Initiated BTIG Research Buy $12
Apr-30-20Upgrade Raymond James Mkt Perform → Outperform
Jun-05-19Downgrade SunTrust Buy → Hold $55 → $5
Jun-05-19Downgrade Robert W. Baird Outperform → Neutral $58 → $6
Feb-08-18Initiated B. Riley FBR, Inc. Buy $40
May-11-23 07:30AM
May-03-23 07:14AM
Apr-18-23 04:01PM
Apr-14-23 04:01PM
Apr-13-23 11:22AM
09:08PM Loading…
Apr-11-23 09:08PM
Apr-07-23 10:21AM
Apr-05-23 11:57AM
Apr-04-23 04:14PM
Mar-23-23 08:21AM
Mar-22-23 07:30AM
Jan-05-23 07:30AM
07:30AM Loading…
Dec-21-22 07:30AM
Nov-09-22 07:40AM
Sep-29-22 07:30AM
Sep-09-22 07:30AM
Sep-08-22 07:30AM
Sep-07-22 10:54AM
Aug-17-22 12:00PM
Aug-11-22 12:00PM
Aug-05-22 07:00AM
Jul-26-22 03:36PM
Jul-06-22 07:30AM
Jun-29-22 12:02PM
07:30AM Loading…
May-17-22 07:30AM
May-13-22 01:55PM
May-12-22 07:30AM
Mar-31-22 02:56PM
Mar-24-22 08:55AM
Mar-17-22 10:03AM
Mar-08-22 07:30AM
Feb-28-22 12:10PM
Feb-16-22 07:30AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-05-22 08:00AM
Nov-15-21 03:39PM
Nov-11-21 07:30AM
Nov-08-21 06:17AM
Nov-05-21 07:30AM
Nov-03-21 07:30AM
Oct-28-21 09:51AM
Oct-27-21 07:30AM
Oct-19-21 10:08AM
Oct-12-21 07:30AM
Sep-09-21 07:30AM
Sep-08-21 07:30AM
Aug-10-21 09:17AM
Aug-06-21 07:30AM
Aug-05-21 07:30AM
Jul-28-21 03:45PM
Jun-17-21 07:30AM
Jun-08-21 07:30AM
May-30-21 05:22AM
May-21-21 07:30AM
May-12-21 07:30AM
May-11-21 04:30PM
Apr-15-21 07:30AM
Mar-25-21 06:30AM
Mar-03-21 07:30AM
Mar-01-21 04:01PM
Feb-25-21 08:30AM
Feb-24-21 04:01PM
Feb-11-21 09:11AM
Jan-11-21 07:30AM
Jan-07-21 07:30AM
Jan-05-21 07:30AM
Dec-08-20 11:35AM
Dec-02-20 08:30PM
Nov-12-20 07:02AM
Oct-29-20 07:00AM
Sep-30-20 04:22AM
Sep-17-20 07:30AM
Sep-14-20 07:30AM
Aug-06-20 07:30AM
Jul-30-20 07:30AM
Jul-24-20 08:55AM
Jul-21-20 07:30AM
Jul-16-20 11:48AM
Jul-09-20 07:33AM
Jun-25-20 04:05PM
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.